200 related articles for article (PubMed ID: 29985536)
1. TERT promoter mutations in solitary fibrous tumour.
Demicco EG; Wani K; Ingram D; Wagner M; Maki RG; Rizzo A; Meeker A; Lazar AJ; Wang WL
Histopathology; 2018 Nov; 73(5):843-851. PubMed ID: 29985536
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutations and prognosis in solitary fibrous tumor.
Bahrami A; Lee S; Schaefer IM; Boland JM; Patton KT; Pounds S; Fletcher CD
Mod Pathol; 2016 Dec; 29(12):1511-1522. PubMed ID: 27562490
[TBL] [Abstract][Full Text] [Related]
3. Telomerase promoter mutations and copy number alterations in solitary fibrous tumours.
Lin Y; Seger N; Tsagkozis P; Hesla AC; Ghaderi M; Chen Y; Ehnman M; Warsito D; Wejde J; Larsson O; Haglund F
J Clin Pathol; 2018 Sep; 71(9):832-839. PubMed ID: 29703757
[TBL] [Abstract][Full Text] [Related]
4. Histological and molecular features of solitary fibrous tumor of the extremities: clinical correlation.
Bianchi G; Sambri A; Pedrini E; Pazzaglia L; Sangiorgi L; Ruengwanichayakun P; Donati D; Benassi MS; Righi A
Virchows Arch; 2020 Mar; 476(3):445-454. PubMed ID: 31463729
[TBL] [Abstract][Full Text] [Related]
5. Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series.
Bertero L; Anfossi V; Osella-Abate S; Disanto MG; Mantovani C; Zenga F; Rudà R; Garbossa D; Soffietti R; Ricardi U; Papotti M; Cassoni P
PLoS One; 2018; 13(9):e0203570. PubMed ID: 30183767
[TBL] [Abstract][Full Text] [Related]
6. Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential.
Akaike K; Kurisaki-Arakawa A; Hara K; Suehara Y; Takagi T; Mitani K; Kaneko K; Yao T; Saito T
Hum Pathol; 2015 Mar; 46(3):347-56. PubMed ID: 25582503
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas.
Vinothkumar V; Arunkumar G; Revathidevi S; Arun K; Manikandan M; Rao AK; Rajkumar KS; Ajay C; Rajaraman R; Ramani R; Murugan AK; Munirajan AK
Tumour Biol; 2016 Jun; 37(6):7907-13. PubMed ID: 26700669
[TBL] [Abstract][Full Text] [Related]
8. Solitary fibrous tumor: a case series identifying pathological adverse factors-implications for risk stratification and classification.
Machado I; Morales GN; Cruz J; Lavernia J; Giner F; Navarro S; Ferrandez A; Llombart-Bosch A
Virchows Arch; 2020 Apr; 476(4):597-607. PubMed ID: 31529158
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
Koelsche C; Renner M; Hartmann W; Brandt R; Lehner B; Waldburger N; Alldinger I; Schmitt T; Egerer G; Penzel R; Wardelmann E; Schirmacher P; von Deimling A; Mechtersheimer G
J Exp Clin Cancer Res; 2014 Apr; 33(1):33. PubMed ID: 24726063
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
12. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
14. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.
Koelsche C; Sahm F; Capper D; Reuss D; Sturm D; Jones DT; Kool M; Northcott PA; Wiestler B; Böhmer K; Meyer J; Mawrin C; Hartmann C; Mittelbronn M; Platten M; Brokinkel B; Seiz M; Herold-Mende C; Unterberg A; Schittenhelm J; Weller M; Pfister S; Wick W; Korshunov A; von Deimling A
Acta Neuropathol; 2013 Dec; 126(6):907-15. PubMed ID: 24154961
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.
Dubbink HJ; Bakels H; Post E; Zwarthoff EC; Verdijk RM
J Neurooncol; 2014 Nov; 120(2):267-72. PubMed ID: 25035100
[TBL] [Abstract][Full Text] [Related]
16. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
Bu R; Siraj AK; Divya SP; Kong Y; Parvathareddy SK; Al-Rasheed M; Al-Obaisi KAS; Victoria IG; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
Int J Cancer; 2018 May; 142(10):2028-2039. PubMed ID: 29266240
[TBL] [Abstract][Full Text] [Related]
17. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
18. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
[TBL] [Abstract][Full Text] [Related]
19. TERT Promoter Mutations but not the Alternative Lengthening of Telomeres Phenotype Are Present in a Subset of Ependymomas and Are Associated With Adult Onset and Progression to Ependymosarcoma.
Brügger F; Dettmer MS; Neuenschwander M; Perren A; Marinoni I; Hewer E
J Neuropathol Exp Neurol; 2017 Jan; 76(1):61-66. PubMed ID: 28040793
[TBL] [Abstract][Full Text] [Related]
20. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
